T hese days, governments, industry and experts seem to be putting biotech forward as a solution to almost everything. The mantra has changed from biotech simply providing cures for disease in developed markets to larger, more global problems. Biotech is now the solution to feeding developing nations. It is the answer to a renewable supply of energy. Or it is a means of reducing the carbon footprint and global warming. Although biotechnologies can certainly help solve these problems, ramming that message down people's throats is hardly likely to convince the doubters. And in the long run, it might even turn out to be counterproductive.
Take a recent case in point: the Biotechnology Industry Organization's (BIO) slogan for its annual meeting held in San Diego in June was "Heal, fuel, feed the world."
On no count is this equivocal or faltering or modest. Of course, perhaps that should be expected of an industry lobby organization whose job it is to proselytize the potential of its members' technology and products. But the problem is the slogan just isn't very realistic.
There are hundreds of thousands of acres of genetically modified (GM) crops being grown around the world, but they are not at present addressing key agricultural problems for poor farmers, such as salinity, desertification and drought. Nor are they addressing problems such as malnutrition (although with Golden Rice, they could). For the moment at least, there are only a handful of GM strains available for food staples (other than corn) widely cultivated in developing countries. Many nations in Africa have a ban on GM seeds.
As for biofuels, such as ethanol, these are being generated from maize in the US and from sugarcane in Brazil. Neither of these approaches has much to do with biotech. Biotech is just one part of the set of technologies and approaches that will be needed to make cellulosic ethanol a reality, among several other alternative renewable energy sources.
And although biotech has addressed a few orphan diseases, produced new therapies in infectious disease, cancer and autoimmune disorders, and recombinant versions of biologics for diabetes and growth disorders, it hasn't delivered on the promised 'cures' of genetic therapies or even the wide adoption of molecularly targeted medicine. Certainly, it hasn't done much to address disease and malnutrition among the world's poor.
This journal champions biotech research, so we are not downbeat on its prospects to, one day, generate products that will heal, fuel and feed the world. That is, nevertheless, an outrageous act of faith bordering on the religious. And the fact is that biotech approaches must be used in the context of other technical and nontechnological solutions. Thus, reason dictates that proponents should be very careful about overhyping what biotech can do now and overpromising what it can do in the future.
